EGFR and neoplasm: For example, in the treatment of lung cancer, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as gefitinib are effective initially, but after long-term use, tumor cells may evade the inhibition of the drug through T790M mutations in the EGFR gene, leading to the development of drug resistance 109.